Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 

Our company continues to grow profitably in the first quarter

New Paths

Immuno-oncology uses the patient’s immune system to attack cancer cells. A promising approach that aims to help more cancer patients in the future.

Award for our company: Best employer

Our company is one of the world’s best employers. This has now been officially verified with the Global Top Employer 2017 certificate. This award acknowledges that we provide exceptional employee conditions, nurture and develop talented people, and always strive to optimize our employment relationships.

 

Media Services for the US and Canada

Our company continues to grow profitably in the first quarter
Our company continues to grow profitably in the first quarter
Darmstadt, Germany, May 18, 2017 – “We again achieved profitable growth in the first quarter. Two approvals for our immuno-oncology medicine in the United States within a short period of time are a great success following long and hard work. We are also further developing our Life Science and Performance Materials business sectors with a targeted focus on innovative technologies. This will create long-term growth opportunities for us.”
 
Our tools for CRISPR technology
Our tools for CRISPR technology
Darmstadt, Germany, May 17, 2017 – Advances in genome editing using “DNA scissors” such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) help to more quickly discover and produce new therapeutic options for conditions that are difficult to treat.
 
Annual General Meeting
Annual General Meeting of Merck KGaA, Darmstadt, Germany, Approves Dividend Increase
Darmstadt, Germany, April 28, 2017 – Merck KGaA, Darmstadt, Germany, announced that at its 22nd Annual General Meeting held today in Frankfurt am Main, shareholders approved a dividend increase of € 0.15 or 14% to € 1.20 per share. Merck KGaA, Darmstadt, Germany, has thus raised the dividend every year since 2011.
 
Merck KGaA, Darmstadt, Germany Divests Biosimilars Business to Fresenius
Merck KGaA, Darmstadt, Germany Divests Biosimilars Business to Fresenius
Darmstadt, Germany, April 24, 2017 – Merck KGaA, Darmstadt, Germany, today announced the divestment of its Biosimilars business to Fresenius. The decision to divest Biosimilars is aligned with the company’s strategy for its Healthcare business sector to focus on its pipeline of innovative medicines.
 
 
top

DOWNLOAD LIBRARY

Download Library
Download images, Media Kits and other material from our media download library

CALENDAR OF EVENTS

Calendar of Events
Find and register for upcoming events

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

FOR MEDIA INQUIRIES, CONTACT

Media Team
POSTAL ADDRESS 
Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250 
64293 Darmstadt 
Germany
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138
 

GENERAL INQUIRIES

Communications Center
Tel.: +49 6151 72-0
Fax: +49 6151 72-2000
 

ANNUAL REPORT 2016

Online Annual Report 2016
Merck KGaA, Darmstadt, Germany on Facebook
Twitter